NEW YORK, March 31, 2017 /PRNewswire/ --
On Thursday, March 30, 2017, the NASDAQ Composite,the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. Taking into consideration yesterday's
San Diego, California headquartered NuVasive Inc.'s stock finished Thursday's session flat at $75.32 with a total volume of 414,817 shares traded. Over the last three months and the previous one year, NuVasive's shares have gained 13.93% and 54.82%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 2.81% and 13.75%, respectively. Shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, are trading at a PE ratio of 109.96. The stock has a Relative Strength Index (RSI) of 58.92. See our free and comprehensive research report on NUVA at:
Leicester, the UK headquartered Steris PLC's stock edged 0.92% higher, to close the day at $69.48. The stock recorded a trading volume of 918,143 shares, which was above its three months average volume of 529,760 shares. Steris' shares have advanced 2.95% in the last three months. The Company's shares are trading 0.54% and 1.28% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide, are trading are trading at a PE ratio of 42.44. Additionally, the stock has an RSI of 53.26. STE free research report PDF is just a click away at:
On Thursday, shares in Redwood City, California headquartered Nevro Corp. ended the session 0.72% lower at $92.94 with a total volume of 319,510 shares traded. Nevro's shares have surged 30.94% in the last three months and 65.20% in the previous one year. The stock is trading 0.77% above its 50-day moving average and 6.00% above its 200-day moving average. Moreover, shares of the Company, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have an RSI of 51.32.
On March 23rd, 2017, research firm Canaccord Genuity initiated a 'Buy' rating on the Company's stock, with a target price of $120 per share. Sign up for your complimentary report on NVRO at:
Smith & Nephew
On Thursday, shares in London, the UK headquartered Smith & Nephew PLC recorded a trading volume of 443,855 shares. The stock ended the day 0.32% lower at $30.88. Shares of the Company, which designs, develops, and sells medical devices worldwide, are trading at a PE ratio of 17.58. Smith & Nephew's stock has advanced 1.88% in the last one month and 4.72% in the previous three months. The Company's shares are trading above its 50-day and 200-day moving averages by 1.91% and 0.03%, respectively. Furthermore, Smith & Nephew's shares have an RSI of 55.66. Register for free on Stock-Callers.com and download the latest research report on SNN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it ...
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...View All